Dividends & Buybacks ·
Biodexa Pharmaceuticals PLC shareholders approved a one-for-10,000 reverse stock split effective July 30, 2026…
BDRXBiodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals PLC shareholders approved a one-for-10,000 reverse stock split effective July 30, 2026, reducing the number of ordinary shares outstanding to 51,453,281. Concurrently, the ADS ratio adjusted from 500,000:1 to 50:1, maintaining proportional ownership and leaving the ADS count at 1,029,063. The company also received authority to allot up to £25,000,000 in new shares through 2029 and adopted new articles of association. Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company developing innovative treatments for gastrointestinal cancers and other diseases.